Fibrosis of adipose tissue (AT) increases AT rigidity, reduces its expandability and contributes to metabolic dysfunction. Collagen type VI, alpha3 (COL6A3) encodes one subunit of a fibrotic extracellular matrix (ECM) protein highly expressed in rodent AT. Knock-out of collagen VI in rodent AT led to a significant improvement in metabolic health in obese, diabetic (ob/ob) mice however, it is unknown whether this collagen has the same metabolic significance in human AT. We therefore aimed to undertake a comprehensive assessment of COL6A3 in relation to human AT and obesity. Characterisation of COL6A3 in human AT showed 5fold higher expression in the stromalvascular fraction compared with adipocyte expression and significantly higher expression in subcutaneous than omental AT. In both depots COL6A3 expression appeared to be lowered in obesity, whilst diet and surgery-induced weight loss increased COL6A3 expression in subcutaneous AT and serum. Leptin treatment caused a dose dependent decrease in COL6A3 expression although no effect was seen with insulin or glucose treatment and no difference observed in subjects with diabetes. In addition, we found that the collagen expression profile in humans differs significantly from rodents as COL6A3 does not appear to be the predominant collagen
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analysis we are performing a within-person analysis (subcutaneous versus omental) . Factoring in these variables is therefore unlikely to make a difference to the gene expression levels. Table 2 could include the mean HbA1c levels of subjects in the very low calorie diet (VLCD). Table 2 as requested.
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Regarding data on
5. Besides reported data on COL6A3 mRNA expression in AT, COL6A3 immunohistological staining reported as data not shown should be included in the manuscript.
We have included an additional figure Fibrosis of adipose tissue (AT) increases AT rigidity, reduces its expandability and contributes to metabolic 44 dysfunction. Collagen type VI, alpha3 (COL6A3) encodes one subunit of a fibrotic extracellular matrix 45 (ECM) protein highly expressed in rodent AT. Knock-out of collagen VI in rodent AT led to a significant 46 improvement in metabolic health in obese, diabetic (ob/ob) mice however, it is unknown whether this 47 collagen has the same metabolic significance in human AT. We therefore aimed to undertake a 48 comprehensive assessment of COL6A3 in relation to human AT and obesity. Characterisation of COL6A3 in 49 human AT showed 5 fold higher expression in the stromalvascular fraction compared with adipocyte 50 expression and significantly higher expression in subcutaneous than omental AT. In both depots COL6A3 51 expression appeared to be lowered in obesity, whilst diet and surgery-induced weight loss increased COL6A3 52 expression in subcutaneous AT. Leptin treatment caused a dose dependent decrease in COL6A3 expression 53 although no effect was seen with insulin or glucose treatment and no difference observed in subjects with 54
diabetes. In addition, we found that the collagen expression profile in humans differs significantly from 55 rodents as COL6A3 does not appear to be the predominant collagen in adipose, muscle or liver. Our findings 56 oppose those initially seen in rodent studies and most importantly, demonstrate a direct regulation of 57 COL6A3 by leptin. This highlights the importance of a paracrine leptin signalling pathway in human AT and 58 suggests an additional mechanism by which leptin can regulate ECM composition and with it AT 59 expandability. and obese subjects whilst histological analysis revealed increased interstitial fibrosis in obesity (5). Fibrosis 80 is defined as an increased accumulation of insoluble fibers, described by increased synthesis, accumulation 81 and reduced degradation of collagens (3). Increased AT fibrosis results in increased ECM rigidity and 82 reduced expandability, and it is hypothesized that this drives ectopic lipid deposition, contributing to insulin 83 resistance and impaired metabolic health. In our previous work we have shown that human omental (OM) 84 tissue, which has a higher fiber content than abdominal subcutaneous (SC) tissue, is restricted with 85 biomechanical tensile testing resulting in a higher elastic modulus, confirming that increased stiffness and 86 decreased expandability are linked with increased collagen deposition in this depot (6). 87
In support of this initial work, microarray analysis of human AT following overfeeding and weight gain has 88 demonstrated increased expression of multiple ECM genes (7), whilst more specifically levels of the ECM 89 regulator and profibrotic protein SPARC have been shown to be upregulated in obese AT and associated 90 with insulin resistance in humans (8). In rodent studies, Chun et al observed that ablation of an ECM 91 remodelling enzyme, matrix metalloproteinase 14 (MMP14), prevented development of white AT leading to 92 a lipodystrophic phenotype in null mice (9) whilst the study of an obese, diabetic rodent model highlighted 93 the ubiquitous up-regulation of multiple collagen subunits compared to control animals (2). Interestingly, 94 amelioration of one collagen subtype, COL6, in obese rodents (ob/ob) led to increased AT expansion, 95 improved insulin sensitivity and a reduced inflammatory profile, suggesting that targeting of this collagen 96 subunit may be beneficial for the appropriate storage of triglycerides in AT (2). However, to date very little 97 work has characterised the role of COL6A3 in human obesity and it is unclear to what degree COL6A3 98 contributes to the total ECM collagen fraction in human AT. As ECM remodelling genes are upregulated 99 with overfeeding (7) we hypothesise that COL6A3 will be increased with weight gain and obesity and 100 downregulated with weight loss. Given the observation that COL6A3 expression is higher in an insulin 101 resistant population of Asian origin (2) we postulate that COL6A3 expression will be higher in the AT of 102 subjects with Type 2 diabetes and will be regulated by treatment with glucose or insulin. 103
The aims of our study were therefore to perform a comprehensive assessment of COL6A3 in human AT; to 104 study its role in human obesity and diabetes, to assess the effect of weight change on expression levels and 105 finally to identify potential regulatory mechanisms which drive COL6A3 expression. 
Materials & Methods 116
Subjects for AT depot study 117
Abdominal SC and OMAT biopsies were obtained from subjects undergoing elective gynaecological surgery 118 at the Royal Devon and Exeter Hospital, Exeter, as part of an ongoing tissue bank initiative. All samples 119
were collected from female subjects with full ethical consent. Subjects with diabetes or malignant diseases 120 were excluded. Lean and obese subjects were matched on a pair-wise basis for age, gender, smoking status 121 and activity levels where known and had the following characteristics: Lean vs Obese (n=15 pairs): Age 122 (years) 44.1±11.6 vs 44.7±11.5 (mean ± SD), p=ns; BMI (kg/m 2 ) 22.5±1.6 vs 33.7±5.5, p<0.001. 123
Individuals were selected from this cohort for within-subject depot specific analysis if both SC and OMAT 124 was available (n=19, Age 45.8±13.6 years, BMI 28.4±7.7 kg/m 2 ). 125
Subjects for diabetes comparison study 126
All subjects used for the diabetes comparison analysis were female. SCAT biopsies were taken from Type 2 127 diabetes (T2DM) subjects undergoing bariatric surgery or from those enrolled onto a clinical trial 128 intervention study at the Exeter Medical School. Samples from subjects without diabetes were collected via 129 routine surgery as detailed above. All samples were collected with full ethical consent. Briefly diabetic and 130 non-diabetic subjects were matched on a pair-wise basis for gender and BMI (36.1 kg/m 2 ± 7.6 vs 36.8 ± 6.4, 131 p=ns, n=9 pairs). HbA1c (mean±SEM) of subjects with T2DM was 50.7±3.0 mmol/mol (range: 34-62). 132
Subjects for bariatric weight loss study 133
UK subjects undergoing weight-loss surgery (n=11) had SCAT biopsies taken during laparoscopic bariatric 134 surgery and on average 9.5±1 months subsequently. Biopsies during the second visit were taken under local 135 anaesthesia. A small incision was made in the abdominal adipose tissue lateral and close to the umbilicus 136 using a scalpel to permit SCAT sampling. Subjects were included in the study if they were aged between 18-137 60 years and had no history of inflammatory disease, malignancy, uncontrolled thyroid disease, muscle 138 conditions or chronic liver injury and had not recently been treated with steroids or hormone replacement 139 therapy. All subjects had fasting bloods taken during both visits as well as a multitude of anthropometric 140 measurements including weight, waist circumference and body composition (measured by Air Displacement 141
Plethysmography technology, Bodpod, Cranlea, UK). This study was approved by the National North West 142 3 Research Ethics committee-Liverpool East. Patient characteristics are reported in Table 1 . Independently, 143 severely obese subjects undergoing sleeve gastrectomy as previously described (10) 
Very low calorie diet study 147
To assess the effect of dietary induced weight loss, 24 obese subjects (BMI 37.6±4.9kg/m 2 ) undertook a 148 450kcal/day very low calorie diet (VLCD) for 16 weeks with a subsequent 2 week re-feeding period. Study 149 assessments were performed at the beginning of the study (week 0), at two intervals throughout the study 150 (week 8 and 16) and two weeks after the VLCD study (week 18) with SCAT biopsies obtained at each time 151 point. The study was conducted in Gothenburg and approved by The Regional Ethics Review Board. 152
Patient characteristics have been reported previously (8,11-13) and a summary is provided in Table 2 . 153
Analyses of association between clinical variables and COL6A3 expression were performed using 154
Generalized Estimating Equations in which COL6A3 mRNA expression was set as the dependent variable, 155 and values of each clinical variable, age, gender and week of follow-up were set as independent variables. 156
Correction was done for repeated measurements in the same individual. All variables have been log 157 transformed to perform the tests of association. 158
Hyperalimentation study 159
To study the effect of overfeeding, 6 lean subjects (BMI 21.4±2.5kg/m 2 ) were enrolled onto a fast food diet 160 for 4 weeks in which caloric intake was doubled and exercise restricted to 5000 steps/day. The study 161 protocol has previously been reported in detail (14) and was approved by The Regional Ethics Committee in 162
Linköping. A summary of subject characteristics is provided in Table 2 . Subjects had SCAT biopsies taken 163 at the start (week 0) and end (week 4) of the study. Computed tomography (CT)-scans were also performed 164 to assess the size of SCAT, visceral AT (VAT) and total AT ( TAT) using a CT HiSpeed Advantage, RP 2.5 165 (GE Medical Systems, Milwaukee, Wisconsin) as previously described (15). 166
Subjects for in vitro explant analysis 167
Matched OM and SCAT biopsies were obtained from 28 female subjects undergoing elective gynaecological 168 surgery as detailed above. The cohort of 28 was split into three groups and 9 matched biopsies processed 169 and treated with recombinant human (rh) leptin, 10 with glucose and 9 with rh insulin. 
Adipose tissue processing 174
AT biopsies for depot-specific analysis or for assessment of weight change related expression were snap 175 frozen in liquid nitrogen at the time of biopsy before being transferred to -80°C for long-term storage. AT 176 samples for in vitro explant analysis were placed into sterile containers containing collection media (1x 177
Hank's balanced salt solution (HBSS), 0.01M Hepes, 2.5µg/ml Amphotericin B and 0.05mg/ml Gentamicin) 178 for transport to the laboratory. 179
Immunohistochemistry 180
Immunohistochemistry was performed as previously described (16). In brief, formalin-fixed, paraffin-181 embedded AT sections were cut at a thickness of 4µm and collected on positive charged microscope slides. 182
De-paraffinisation, rehydration and immunohistochemistry were carried out by the Bond™-MAX autostainer 183 at room temperature. Slides were treated with or without COL6A3 antibody (1:100; Ab49273 [Abcam]). 184
Staining was also performed in testes as a positive control. 185
Primary explant culture to assess physiological regulators of metabolism 186
Samples were processed for explant culture using a modification of . 187
Briefly, samples were washed in 1xPBS (1% pen/strep) and minced into 5-10mg pieces. Tissue was rinsed 188 through a 230µm nylon mesh using 1xPBS and M199 culture media. Samples were transferred to six well 189 plates (~250mg/well) with 3ml M199 media, supplemented with 5% foetal calf serum and 1% 190 penicillin/streptomycin. Explants were cultured for 24 hours at 37°C under an atmosphere of 5% carbon 191 dioxide/95% air in the presence of varying concentrations of glucose, rh leptin (Cambridge Biosciences, 192 UK), or insulin (Sigma Aldrich, UK). All treatment conditions were performed in triplicate. 193
Adipocyte isolation protocol 194
AT biopsies were minced into small fragments using scalpels before sequentially washing four times in 1x 195
Hank's buffered salt solution (HBSS) to remove contaminating blood. Tissue was enzymatically digested in 196 1mg/ml collagenase (Gibco, Life Technologies) in HBSS for 1 hour at 37°C with gentle agitation. 
RNA extraction and processing 201
Total RNA from AT acquired in the VLCD study was extracted using the Qiagen RNeasy lipid tissue kit as 202 per manufacturer's instructions. RNA from all other samples was extracted using the phenol-chloroform-203
guanidinium-thiocyanate method (18). Briefly ~100mg tissue was homogenised in Tri reagent (Life 204
Technologies) using a Retsch Mixer Mill MM400 in accordance with manufacturer's instructions. RNA 205 quantity was determined spectrophotometrically using Nanodrop technology. RNA was treated with DNase 206 I (ThermoScientific) to remove residual genomic contamination before 500ng was reverse transcribed in a 207 random primed single strand synthesis reaction using high capacity reverse transcriptase (Life Technologies). 208
Gene expression analysis 209
COL6A3 expression in subjects in the VLCD study was determined using the Human Genome U133A DNA 210 microarray (Affymetrix) whilst in the hyperalimentation study, expression was determined using HG-211 U133Plus2.0 (Affymetrix) as previously described (19) . COL6A3 expression in all other samples was 212 determined using qRT-PCR with Taqman technology. Briefly, cDNA was diluted in 0.01M Tris HCl before 213 amplification with a COL6A3 specific expression assay (Hs00915125_m1) or expression assays for the 214 housekeeping genes PPIA (Hs99999904_m1) or UBC (Hs00824723_m1) using Universal PCR mastermix 215 (Life Technologies). All samples were amplified in triplicate for each assay and were run alongside a 216 standard curve to allow assay efficiency determination. Expression analysis of COL1A1 (Hs00164004_m1), 217 COL3A1 (Hs00943809_m1), COL4A1 (Hs00266237_m1) and COL5A3 (Hs00210526_m1) were also 218 determined in AT explants following leptin treatment. COL6A3 expression change following bariatric 219 surgery was determined, alongside other collagen subunits, using a Taqman Low-Density Array, following 220 normalising to the geometric mean of 4 housekeeping genes (PPIA, UBC, GAPDH and PGK1). 221
Amplification was performed using an ABI7900 thermal cycler with the following cycling parameters: 50°C-222 2 minutes, 95°C-10 minutes, 40 cycles (95°C-15 seconds, 60°C-1 minute). mRNA expression analysis in 223 the Norwegian bariatric subjects was normalised to TBP. Gene expression levels were calculated using the 224
2^-
ΔΔCt analysis method modified by Pfaffl (20) and are presented as Arbitrary Units (AU). 225
Serum analysis 226
Blood was taken from subjects during and 9 months post bariatric surgery for analysis of adipokines, glucose 227 and insulin. The Homeostatic Model Assessment (HOMA) method was used to assess beta-cell function 228 (HOMA-β) and insulin sensitivity (HOMA-IR) (21). Serum insulin levels were assessed using Immunoassay 229 from Cobas-Roche (Sussex, UK) with sensitivity of 0.2µU/ml and intra-assay coefficients of variation of 230 2.5-4.9%. Serum leptin levels were assessed using ELISA from Millipore (Watford, UK) with sensitivity of 231 0.5ng/ml with intra-assay coefficients of variation of 2.6-4.6%. COL6A3 ELISA was purchased from USCN 232 Life Science (E92148HU, Oxford Biosystems, UK) with sensitivity of 13.4pg/ml and intra-assay coefficient 233 of variation of <10%. All ELISAs were performed in line with manufacturers' guidelines. 234
Statistical analysis 235
All data are presented as mean±SEM unless otherwise stated. Within-subject, lean versus obese and diabetic 236 versus non-diabetic comparisons were made using the non-parametric Wilcoxon signed rank test. 237
Comparison before and after weight change within subjects in the VLCD and hyperalimentation study were 238 performed with a paired two-tailed t-test. For BMI and COL6A3 expression analysis, data were log 239 transformed to achieve normality before Pearson Correlation Coefficients were determined. 
Results
262
COL6A3 depot specific expression 263
To begin, we determined in which AT cell type and depot COL6A3 predominates. AT is comprised not only 264 of adipocytes but also fibroblast derived preadipocytes, endothelial cells and immune cells which 265 collectively comprise the stromalvascular fraction (SVF). To determine which cell types contribute to AT 266 COL6A3 expression, omental AT from six healthy subjects was fractionated using collagenase to separate 267 mature adipocytes from the SVF. Expression analysis within these distinct cellular populations 268 demonstrated that AT COL6A3 mRNA levels are predominantly contributed to by cells of the SVF. Mean 269 expression level (±SEM) within this fraction was 2.0±0.4 AU compared to 0.4±0.1 AU in mature adipocytes 270 (p<0.05, Figure 1A) . 271
Next we analysed the within-subject depot specific expression of COL6A3 in two independent cohorts, on 272 both occasions observing significantly higher COL6A3 expression within abdominal SC compared to OMAT 273 ( Figure 1B&C ). In the first population, a cross-sectional cohort of healthy female subjects, we observed that 274 COL6A3expression was 1.2±0.1 AU (mean±SEM) in SC tissue compared to 0.9±0.1 AU within OM samples 275 (n=19, p<0.01, Figure 1B) . In a separate cohort of subjects undergoing bariatric surgery, consisting of both 276 men and women, we again observed the same depot specific trend with SCAT showing higher expression 277 than OMAT (SC v OM: 2.0±02 vs 1.2±0.1AU, n=11, p<0.01, Figure 1C) . 278
COL6A3 expression and BMI 279
To determine whether COL6A3 is differentially expressed with obesity, our Exeter depot cohort was 280 subdivided into lean (BMI<25kg/m 2 : 22.5±1.6 [mean±SEM] kg/m 2 ) and obese (≥25kg/m 2 , 33.7.4±5.5kg/m 2 ) 281 subjects. When comparing expression levels within OMAT we saw a trend towards reduced expression 282 within obese subjects compared to lean (0.7±0.1 vs 1.0±0.1 AU, n=13, p=0.22, Figure 1D ) although this did 283 not reach statistical significance. A similar trend was also observed in SCAT although this once again failed 284 to reach statistical significance (obese vs lean: 1.1±0.1 vs 1.3±0.1 AU, n=11, p=0.47, Figure 1D ). SCAT is 285 essential for buffering surplus free fatty acids in times of energy excess. Dysregulation of ECM within this 286 depot is hypothesised to increase fibrosis, reducing the ability of AT to expand by suppressing adipogenesis 287 and limiting adipocyte hypertrophy, all of which contribute to ectopic fat deposition. Diversion of 288 triglyceride storage from subcutaneous to ectopic tissues, as seen in lipodystrophy, increases insulin 289 resistance and the risk of diabetes (22) . With this in mind we focussed the majority of our further analysis on 290 assessing the expression of COL6A3 in the SCAT depot. 291
COL6A3 expression and diabetes 292
Kahn et al demonstrated significantly higher levels of COL6A3 in a population of Asian Indians who show 293 increased susceptibility to insulin resistance (2). To ascertain whether this correlation with impaired insulin 294 sensitivity is true in other ethnic populations we determined COL6A3 expression in the SCAT of Caucasian 295 subjects with or without T2DM. All subjects were individually matched for gender and BMI. No significant 296 difference in expression was determined between these two groups (0.8±0.1 vs 0.9±0.2 AU, n=9, p=ns, data 297 not shown). 298
COL6A3 expression and weight change 299
Three independent cohorts were used to assess the effects of weight gain or weight loss on SCAT COL6A3 300 expression levels. (1) Subjects gaining weight after four weeks of fast food dieting in the hyperalimentation 301 study as described above, (2) subjects undergoing a 16 week VLCD diet followed by 2 weeks of refeeding, 302 and (3) subjects before and after bariatric surgery. COL6A3 expression was determined in SCAT biopsies 303 before and after each of these dietary or surgical interventions. 304
(1) COL6A3 and hyperalimentation 305 SCAT biopsies were taken from lean subjects at baseline and following four weeks of a high calorie diet 306 (Table 2) . As shown in Figure 2A , COL6A3 expression was not significantly altered despite significant 307 weight gain at the cessation of the study (week 0 vs week 4 [mean±SEM]: 2036±803 vs 2574±641 AU, n=6, 308 p=ns). 309 (2) COL6A3 and VLCD 310
As described in the method section, biopsies were taken from 24 subjects at baseline and following 16 weeks 311 of a low calorie diet ( Table 2) . As shown in Figure 2A 
001). 313
Refeeding without weight gain (weeks 16-18) did not significantly affect COL6A3expression levels. We 314 next determined the association between COL6A3 and metabolic parameters during the course of the weight 315 loss intervention (Table 3) . COL6A3 mRNA levels negatively correlated with BMI, HbA1c and HOMA-IR 316 (if uncorrected for BMI). Of interest, COL6A3 was found to be negatively associated with both leptin mRNA 317 in SCAT (p<0.0001) and serum leptin levels (p=0.0015). 318 (3) COL6A3 and bariatric surgery induced weight loss 319 SCAT biopsies were taken from 11 obese subjects during bariatric surgery and on average 9.5±1.1 months 320 post-surgery. In this time period subjects lost on average 26.1kg, reducing their BMI by 8.5kg/m 2 , and 321 improving a number of other associated metabolic parameters as shown in Table 1 . Following surgery, 322
SCAT COL6A3 expression was increased 1.6-fold (2.0±0.2 vs 3.2±0.6 AU, n=11, p<0.05, Figure 2B ). There 323 was a concomitant increase in serum COL6A3 levels post-surgery (133.3±12.2 vs 146.5±11.2ng/ml, n=8, 324 p=ns, Fig 2E) whilst a significant reduction in circulating leptin levels was also observed at this time point 325 (57.7±7.2 [mean±SEM] vs 18.2±5.1ng/ml, n=11, p<0.01, Figure 2F ). Bivariate-Pearson correlation analysis 326 highlighted a significant negative association between SCAT COL6A3 expression and BMI (r=-0.57, p<0.01, 327 Figure 2G ), an association which was also observed when correlating SCAT COL6A3 expression and 328 circulating serum leptin levels (r=-0.69, p<0.01, Figure 2H ). 329
To determine from which cell type the changes in COL6A3 mRNA were arising, we measured COL6A3 330 mRNA expression in adipocytes and SVF cells from an independent cohort of severely obese subjects before 331 and one year after bariatric surgery (n=5, age 44.2±9.5 years, BMI 46.44± 4.8[mean±SEM] before and 332 33.34±6.3kg/m 2 after surgery). In isolated adipocytes there was no consistent change in COL6A3 expression 333 after profound surgical weight loss (p=0.937) ( Figure 2C ). On the other hand, in the SVF we found a 334 significant 3.6-fold increase in COL6A3 mRNA expression (p=0.043) (Wilcoxon signed rank test) (Figure  335   2D) . 336
COL6A3 expression and physiological regulators of metabolism 337
The negative correlation between leptin and AT COL6A3 in both the diet and surgery-induced weight loss 338 cohorts prompted us to investigate whether COL6A3 may be directly modulated by physiological regulators 339 of metabolism. In particular we wanted to study regulation by leptin and, due to the presumed association 340 with insulin resistance as previously reported (2), we also wanted to assess modulation by glucose and 341 insulin. SCAT explants (1mm 3 whole adipose tissue fragments) were treated with varying concentrations of 342 rh leptin (0.01nM, 10nM and 100nM), insulin (0.01nM, 10nM and 100nM) and glucose (5mM, 10mM and 343 20mM) for 24 hours in culture and expression levels compared to control explants (explants cultured for 24 344 hours in the absence of the metabolic regulator). Treatment with insulin and glucose had no effect on 345 Figure 3A ). Leptin treatment also caused a significant downregulation of COL1A1 at 350 100nM vs Control (0.47±0.08 vs 0.68±0.07, n=9, p<0.05, Figure 3B ). There was no change in expression of 351 any other collagen subunit when cultured with leptin for 24 hours. 352
AT ECM collagen distribution 353
In order to establish whether, like rodents, COL6A3 is the predominating collagen in human AT, we 354 determined the expression profile of multiple collagen subunits across a range of metabolically relevant 355 tissues. Using TLDA gene expression technology we simultaneously determined the collagen expression 356 profile in human AT, liver and muscle biopsies, obtained from subjects undergoing bariatric surgery 357 (described above). COL5A3 was most highly expressed within liver, with levels four-fold higher than any 358 other of the tested collagen subunits ( Figure 4A ). Interestingly, although COL6A3 is one of the most 359 predominantly expressed collagens within muscle, this same expression pattern does not translate to AT, 360 with COL6A3 expression within both OM and SCAT being strikingly lower than COL1A1, COL3A1 and 361 COL4A1 ( Figure 4A ). Immunostaining showed that COL6A3 is distributed in the pericellular space of 362 omental AT ( Figure 4B) . 363 364 365
Discussion 366
The ability of AT to expand in times of positive energy balance and retract during negative energy balance is 367 an essential homeostatic mechanism, permitting buffering of daily lipid flux and mobilisation of an essential 368 fuel source respectively. For AT to expand, remodelling of the ECM must occur, permitting both growth of 369 existing adipocytes and differentiation of precursor cells. Increased deposition of fibrous proteins within the 370 ECM has been shown to lead to increased rigidity and reduced AT expandability (9), and increased SCAT 371 fibrosis is considered to be a driving force behind ectopic fat deposition. The negative health implications of 372 ectopic fat deposition are clearly seen in patients with lipodystrophy, where storage of triglycerides in sites 373 external to AT correlates with insulin resistance and diabetes (22). Khan et al. have previously highlighted 374 the metabolic benefits of knocking out a fibrous ECM collagen subunit (COL6) in a genetically predisposed 375 obese rodent model (2). Ob/ob mice, who are otherwise metabolically compromised, were shown to have 376 increased insulin sensitivity, despite hypertrophic adipocytes, and a reduced AT inflammatory profile when 377 COL6 was knocked out (2). Evidence from this study suggested that in rodents at least, accumulation of 378 COL6 may be a significant factor contributing to reduced AT expandability with overfeeding (2). 379
Our study investigates whether the same applies to human physiology. Our data suggest that COL6A3 380 expression is significantly higher in SCAT when directly compared to OMAT using within-subject paired 381
analysis. This expression pattern was observed not only in a cross-sectional population of healthy female 382 subjects, but also in subjects undergoing bariatric surgery, highlighting that the depot specific differences are 383 not driven by BMI, but remain true across all weight ranges. Whilst increased SCAT fat mass is 384 metabolically more favourable, fibrosis in SCAT, as is also observed in subjects with lipodystrophy, is 385 linked with insulin resistance/diabetes (16, 22) . With the finding of a higher expression in SCAT our results 386 question whether COL6A3 takes part in obesity induced fibrosis given its reduced expression in obese SCAT 387
given our observation of a consistent trend of lower expression with increasing BMI. Interestingly, our 388 findings are in contradiction to those reported by Pasarica et al (23) . In their depot specific analysis, 389 significantly higher COL6A3 expression levels in visceral compared to SCAT were found alongside a 390 positive correlation between BMI and COL6A3 SCAT expression (23). There are multiple explanations as to 391 why our observed expression patterns vary including (1) differences in the site from which biopsies were 392 obtained, (2) variations in the methodology used to obtain biopsies, (3) design of probes to accurately 393 quantify gene expression levels and/or, (4) variations in subject gender with lower COL6A3 expression in 394 women (23). To gain conclusive results regarding the expression levels of AT COL6A3 with variable fat 395 mass, we performed a more comprehensive assessment of COL6A3 expression following diet and surgery-396 induced weight loss and dietary-induced weight gain, in subjects matched for gender where indicated. 397
398
In line with the findings in our initial cross-sectional study we found that weight loss, both diet and surgery-399 induced, led to an increase in SCAT COL6A3 mRNA expression. Our findings are in line with other 400 analyses in which COL6A3 expression was found to be elevated following bariatric surgery (5,24), however 401 as far as we are aware, we are the first to show that there is also a significant increase in expression 402 following diet-induced weight loss, which was of a similar magnitude to surgery-induced weight loss. We 403 observed an increase in COL6A3 in the serum of subjects post-surgery, however this did not reach statistical 404 significance, nor did levels correlate with COL6A3 expression in SCAT (data not shown). Whilst this may 405 require a larger sample size, it is pertinent to remember that collagen is under continuous turnover by 406 metalloproteinases and its inhibitors and other sources of COL6A3, other than AT, are likely to dilute any 407 association. Due to scarcity of sample we were unable to directly assess COL6A3 protein levels in AT of 408 these weight loss subjects. We extended our study to also assess COL6A3 expression in relation to the 409 hyperalimentation-induced weight gain but were unable to identify a significant change in expression. 410
Though the number of AT biopsies obtained for this study was small (n=6) (as subjects who failed to adhere 411 to the diet and/or failed to gain weight were excluded), the biopsies assessed were from subjects who 412 achieved substantial weight gain as shown in Table 2 (14) . Of note, the weight gain observed in our 413 hyperalimentation study is of a similar magnitude to the weight gain reported in Pasarica's study, in which a 414 significant increase in COL6A3 was reported (23). Lack of correlation in our study may be explained by the 415 small effect of weight gain on COL6A3, the relatively short duration of the study or higher baseline COL6A3 416 levels in our subjects, which due to the low BMI of our subjects are less likely to increase, as suggested by 417 Pasarica (23). Similarly, and consistent with this, we did not find a change in COL6A3 expression after 418 refeeding following dieting in the VLCD study. 419
420
We have not found elevated or different levels of COL6A3 in subjects with T2DM when compared to BMI-421 matched non-diabetic subjects, which is similar to previous findings (23), nor did we observe changes in 422 COL6A3 expression in response to glucose or insulin treatment. However, one of the most interesting 423 observations from our study is the strong correlation between COL6A3 expression and leptin. Leptin is 424 secreted from adipocytes in proportion to fat mass and is a regulator of satiety (25). In patients undergoing 425 bariatric surgery, and those on a VLCD, we see a significant negative correlation between SCAT COL6A3 426 expression and circulating serum leptin levels, suggesting that as leptin levels (and therefore obesity) 427 increase, COL6A3 mRNA levels decrease. To further investigate this novel association we treated primary 428 human SCAT explants with rh leptin and observed a dose-dependent reduction in COL6A3 expression with 429 increasing leptin concentration. Our data therefore suggest a direct regulatory effect of leptin on the 430 expression of COL6A3. Leptin receptors are present on the surface of adipocytes and autocrine/paracrine 431 leptin signalling within adipocytes is known to occur to induce functions such as lipolysis (26, 27) . In 432 rodents, AT-specific knockout of the leptin receptor was shown to result in increased adiposity and an 433 impaired metabolic phenotype (28) whilst experimentally induced hyperleptinaemia was shown to deplete fat 434 mass, which may in part be explained via increased lipolysis (29). This data clearly points to the presence of 435 a paracrine feedback mechanism within AT by which leptin is controlling fat mass. There is also evidence of 436 a paracrine feedback mechanism in human AT. In 2012, Singh et al demonstrated that leptin treatment of 437 differentiating human adipocytes resulted in increased expression of the plasma membrane protein Caveolin 438 1, which in turn impaired leptin signalling preventing leptin-mediated reduction in lipid accumulation (30) . 439 This may suggest that in humans, feedback mechanisms exist by which leptin is able to mediate the storage 440 of triglycerides in a safe manner in times of triglyceride excess and hyperleptinaemia. 441
Leptin binding to its receptor has been shown to activate a number of downstream signalling pathways and 442 secondary messengers including ERK and JAK/STAT (30), all of which could be hypothesised to modulate 443 expression levels of COL6A3. Investigation of the specific mechanisms of regulation were deemed to be 444 beyond the scope of this manuscript but will warrant further investigation to determine how physiological 445 regulators of metabolism are able to modulate ECM gene expression levels. Our observation that COL6A3 446 expression levels may change with weight only in the SVF, compared to adipocytes, needs further 447 investigation. In particular, understanding the relevance of Col6 in endothelial maturation and its expression 448 in newly formed vessels will be pertinent given the vascular rarefaction observed with obesity. This may go 449 some way to explaining the higher levels observed with lower BMIs (31,32). Collagen VI is also expressed 450 in AT macrophages as recently shown by Spencer at al (33) who identified an association between COL6A1 451 expression and AT inflammation and reduced insulin sensitivity. However, we studied more specifically 452 COL6A3 expression and COL6A3 immunostaining and therefore our results are unlikely to be directly 453 comparable with this study. Previous studies suggest non-coordinate regulation of the mRNA expression of 454 COL6 alpha chains such as in wound healing (31) which may explain the different characteristics. 455
456
Our observation that AT COL6A3 expression does not increase with obesity or metabolic parameters in 457 human subjects is in stark and direct contradiction to previous studies performed in rodents (2). Although it 458 is feasible that the disparity in findings may be due to species differences, we feel another possible 459 explanation may pertain to the system in which COL6 was knocked down in rodents. Initial studies 460 performed in db/db mice demonstrated elevated levels of AT Col6a3 compared to wildtype animals whilst 461 knockout of COL6 was performed in an ob/ob model (2). It is pertinent to consider that in both of these 462 models of obesity and diabetes, the leptin signalling pathway has been genetically silenced at the level of the 463 receptor or the adipokine respectively. Our data clearly demonstrate the importance of a paracrine leptin 464 signalling pathway in regulation of human AT COL6A3 expression, and it is therefore possible that loss of 465 leptin signalling in the rodent models may be driving the increase in Col6a3, a phenomenon which may not 466 necessarily be seen in physiological obesity, when leptin levels are high. Therefore in the future, it may be 467 relevant to assess the effects of COL6 knockdown in an in-vivo situation in which leptin and its receptor 468 remain functional. 469
470
Leptin is a pro-inflammatory cytokine and we have previously shown it is able to potently increase levels of 471 the profibrotic matricellular protein SPARC in human AT (8) . This would suggest leptin influences ECM 472 fibrosis. Data from our current study however suggests that leptin is also able to downregulate ECM 473 components in an obesogenic environment. Although rodent data suggest Col6a3 to be the most highly 474 expressed collagen in AT (2), our human data suggest that the contribution of COL6A3 to total collagen 475 levels is minimal. Similarly immunohistochemical data from human subjects has shown that COL6A3 does 476 not reside within fibrous bundles of AT, but was found by us and by others in the pericellular space 477 surrounding adipocytes (23, 34) . Its position around the adipocytes may if in surplus limit the expandability 478 of existing fat cells by increasing cell rigidity as demonstrated by Chun by which a rigid network limits 479 adipocyte hypertrophy and adipogenesis (9). This would be a concern should we have found COL6A3 to be 480 increased in obesity yet our findings do not support its contribution to AT fibrosis if we assume to reserve 481 this term to describe the obesity associated increase in AT collagens. 482
483
Leptin modulates ECM remodelling and as such its expansion by several mechanisms which we have 484 outlined in a diagrammatic flowchart ( Figure 5 ). It is expressed and secreted in relation to fat mass and 485 upregulated by hypoxia, which amongst others develops as result of growing oxygen diffusion distance 486 between increasingly distant blood vessel and hypertrophied cells in obese AT. Hypoxia increases leptin 487 independently by amongst others an upregulation of HIF1A (35,36). As mentioned above, leptin may 488 stimulate AT fibrosis by increasing expression of the fibrotic genes SPARC and TGF-beta, the latter as 489 demonstrated in the peritoneal mesenthelial cells (37). In contrast to its profibrotic action, leptin has also 490 been shown to increase expression of the membrane protein Caveolin which in turn impairs leptin signalling 491 preventing leptin-mediated reduction in lipid accumulation (30). In line with this, we have shown that at 492 high doses leptin decreases COL6A3 which may allow free expansion and safe storage of surplus fatty acids. 493
With its profibrotic and potentially proinflammatory actions, leptin promotes AT dysfunction whilst it also 494 appears to be able to preserve AT expandability, a contradictory observation. Adding to the complexity is the 495 potential of peripheral leptin resistance in obesity which may selectively attenuate certain properties but not 496 others. Further research is required to disentangle in which tissue leptin takes on specific roles as it may have 497 similar characteristics to SPARC which is multifunctional and its function dependent on cellular 498 environment and tissue type (38) . 499
In conclusion, we have demonstrated that in humans, unlike rodents, COL6A3 expression does not correlate 501 with impaired metabolic health, does not respond to variations in insulin but conversely decreased with 502 obesity. The observation that COL6A3 expression levels increase following weight loss, coupled with our 503 data highlighting the direct repression of COL6A3 following leptin treatment, suggest the presence of a 504 potential paracrine regulatory mechanism in which leptin is able to modulate levels of this pericellular 505 collagen to regulate ECM remodelling. This confirms previous observations of leptin as a potent modulator 506 of the ECM in human AT. 507
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